Skip to main content

Table 4 Mean and standard deviation as well as the difference between the mean of drug evaluation indices before and after the intervention in the studied groups

From: Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

Drugs Index I2 Begg and mazumdar rank correlation test Mean ± SD before intervention (drug group) Mean ± SD after intervention (drug group) Mean difference and standard deviation before and after the intervention
Mycophenolate MG-ADL 85.3 1.000 5.9 ± 0.87 7.5 ± 4.09 1.4 ± 0.9
SFEMG 0 71.5 ± 11.3 60.5 ± 13.1 0.9 ± 0.56
Anti-AChR antibodies 79.1 11.1 ± 2.1 5.5 ± 2.4 1.9 ± 1.5
QMGS 67.9 0.734 12.3 ± 0.71 8.1 ± 0.59 1.4 ± 0.77
Immunoglobulin or plasma exchange MG-ADL 78.5 1.000 8.2 ± 1.3 4.4 ± 0.84 1.3 ± 0.63
SFEMG 43.5 1.000 82.2 ± 1.43 54.5 ± 27.5 1.5 ± 0.73
Anti-AChR antibodies 99.8 1.000 10.8 ± 4.6 52.7 ± 34.1 –2.006 ± 0.78
QMGS 98.6 0.391 11.2 ± 1.6 9.4 ± 1.8 0.62 ± 0.28
Corticosteroids QMGS 99.4 7.08 ± 1.09 5.9 ± 2.2 1.64 ± 1.6